172 related articles for article (PubMed ID: 31043416)
1. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
Martinez-Usatorre A; Sempere LF; Carmona SJ; Carretero-Iglesia L; Monnot G; Speiser DE; Rufer N; Donda A; Zehn D; Jandus C; Romero P
Cancer Immunol Res; 2019 Jun; 7(6):1013-1024. PubMed ID: 31043416
[TBL] [Abstract][Full Text] [Related]
2. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
3. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
4. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
5. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
6. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
9. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
10. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
11. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
[TBL] [Abstract][Full Text] [Related]
12. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
13. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
[TBL] [Abstract][Full Text] [Related]
14. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
15. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
16. TCR Repertoire Analysis Reveals Mobilization of Novel CD8
Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K
Front Immunol; 2018; 9():3185. PubMed ID: 30733724
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
18. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Kim SH; Roszik J; Cho SN; Ogata D; Milton DR; Peng W; Menter DG; Ekmekcioglu S; Grimm EA
Clin Cancer Res; 2019 Mar; 25(5):1650-1663. PubMed ID: 30538110
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.
Straetemans T; Berrevoets C; Coccoris M; Treffers-Westerlaken E; Wijers R; Cole DK; Dardalhon V; Sewell AK; Taylor N; Verweij J; Debets R
Mol Ther; 2015 Feb; 23(2):396-406. PubMed ID: 25363716
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.
Haymaker CL; Kim D; Uemura M; Vence LM; Phillip A; McQuail N; Brown PD; Fernandez I; Hudgens CW; Creasy C; Hwu WJ; Sharma P; Tetzlaff MT; Allison JP; Hwu P; Bernatchez C; Diab A
Cancer Immunol Res; 2017 Feb; 5(2):100-105. PubMed ID: 28062513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
